Compare Freeport-McMoRan Inc (FCX) vs TG Therapeutics Inc (TGTX) Price & Performance

Freeport-McMoRan (FCX) trades at $73.69, up 2.54% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $25.9B revenue, 11.38% net margin, and positive cash flow trends. Recent news highlights copper demand growth from AI/data centers, positioning FCX to benefit from favorable commodity trends while managing cost pressures.

FCX presents a mixed outlook with analyst consensus at Buy (61%) and $73.27 price target near current levels. Upside potential exists from copper's structural deficit and expansion projects, but risks include rising production costs, margin pressure, and ongoing legal investigation. The stock offers exposure to copper's AI-driven demand while facing execution challenges in a volatile commodity environment.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.